Isaac Ciechanover an Insider in Atara Biotherapeutics, Inc. (ATRA) Sold 600 Shares; John Hancock Preferred Income Fund II (HPF) Sentiment Is 0.93

The stock decreased 0.76% or $0.16 during the last trading session, reaching $20.93. About 74,229 shares traded or 107.46% up from the average. John Hancock Preferred Income Fund II (HPF) has risen 1.51% since January 19, 2017 and is uptrending. It has underperformed by 15.19% the S&P500.

Isaac Ciechanover, an insider of Atara Biotherapeutics Inc, currently Chief Executive Officer recently disclosed a substantial transaction with the SEC. As shown in the document, Isaac Ciechanover purchased 600 shares of the company, priced at $30.4 per share. $18,228 U.S. Dollars was the transaction’s value. The SEC report’s date was 18/01/2018. He also sold 50,900 shares with a total value of about $1,019,801 USD in the last month. Having been a very massive insider transaction at Atara Biotherapeutics Inc, the probability that it remains ignored for long was obviously very low. Isaac Ciechanover currently has ownership of 1.10 million shares which are roughly 3.61% of the California-Company’s total market cap.

Fiduciary Financial Services Of The Southwest Inc Tx holds 0.99% of its portfolio in John Hancock Preferred Income Fund II for 150,515 shares. Koshinski Asset Management Inc. owns 81,764 shares or 0.59% of their US portfolio. Moreover, Rocky Mountain Advisers Llc has 0.09% invested in the company for 1,000 shares. The Florida-based Ifc Holdings Incorporated Fl has invested 0.06% in the stock. Provise Management Group Llc, a Florida-based fund reported 11,500 shares.

Analysts await Atara Biotherapeutics, Inc. (NASDAQ:ATRA) to report earnings on March, 8. They expect $-1.14 EPS, down 80.95% or $0.51 from last year’s $-0.63 per share. After $-1.02 actual EPS reported by Atara Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.76% negative EPS growth.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States. The company has market cap of $841.39 million. The Company’s clinical stage T-cell product candidates include ATA129 that focuses on Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus associated post-transplant lymphoproliferative disorder after hematopoietic cell transplant and solid organ transplant; ATA188, which is in Phase I clinical trial for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product targeting cancers expressing the antigen Wilms tumor 1; and ATA230, which is Phase III clinical trials for refractory cytomegalovirus. It currently has negative earnings. The firm is also developing a next generation of allogeneic T-cell product candidates utilizing a technology to selectively enhance a T-cellÂ’s ability to target specific viral proteins implicated in disease.

Since August 10, 2017, it had 0 buys, and 16 insider sales for $2.51 million activity. 28,700 shares valued at $613,843 were sold by Ciechanover Isaac E. on Wednesday, January 10. Soffer Gad sold 9,464 shares worth $140,802. Shares for $16,931 were sold by Gallagher Carol Giltner. 37,000 shares valued at $900,815 were sold by MCGRATH JOHN on Thursday, January 11. Haqq Christopher also sold $112,159 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Tuesday, August 15. 3,021 Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares with value of $43,291 were sold by Clark Mitchall G.

The stock decreased 2.65% or $0.75 during the last trading session, reaching $27.5. About 655,029 shares traded or 23.57% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since January 19, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.